Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

234.33 7.01 +3.08%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 62.6×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC (JAZZ) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a price to free cash flow of 22.2×. Over the past ten years it has ranged from 4.0× (May 2025) to 67.0× (March 2015); the current reading is higher than 88% of that period. That is below the Biotechnology industry median of 24.8× and in line with the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/JAZZ/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Jazz Pharmaceuticals PLC price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/JAZZ/metrics/price-to-free-cash-flow">Jazz Pharmaceuticals PLC (JAZZ) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	32.8×	480.39%
FY2024	5.7×	(26.22%)
FY2023	7.7×	(39.40%)
FY2022	12.6×	21.80%
FY2021	10.4×	(41.28%)
FY2020	17.7×	26.87%
FY2019	13.9×	32.50%
FY2018	10.5×	(26.18%)
FY2017	14.2×	(13.65%)
FY2016	16.5×	(19.85%)

Period	Price to free cash flow	Change
Sep 2026	22.5×	109.66%
Jun 2026	10.8×	(71.18%)
Mar 2026	37.3×	13.75%
Dec 2025	32.8×	407.89%
43 more quarters	Free account

Against its own ten years

Low 4.0× High 67.0×

Ten-year median 13.5×

Current reading's percentile 88

Company	Price to free cash flow
KYMR Kymera Therapeutics, Inc. compare	n/m
SMMT Summit Therapeutics PLC compare	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
EXEL Exelixis, Inc. compare	14.8×
HALO Halozyme Therapeutics, Inc. compare	15.9×
BMRN BioMarin Pharmaceutical Inc. compare	20.0×
JAZZ Jazz Pharmaceuticals PLC	22.2×
ASND Ascendis Pharma A/S compare	42.1×
TECH Bio-Techne Corp compare	43.1×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Jazz Pharmaceuticals PLC (JAZZ) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on JAZZ

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on JAZZ

Stockrow Weekly